Prothena is a clinical-stage neuroscience company. Co. is developing a pipeline of therapeutic candidates for a number of indications and targets. Co.'s partnered programs include prasinezumab (PRX002/RG7935) for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target for the potential treatment of Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia or other neurodegenerative diseases. Co.'s proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target Amyloid beta for the potential treatment of Alzheimer's disease. The PRTA stock yearly return is shown above.
The yearly return on the PRTA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRTA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|